{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:49:25Z","timestamp":1794962965093,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01294-w","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:12:35Z","timestamp":1755753155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Harm reduction measures in a recreational gym user with anabolic androgenic steroid dependence: a case report in the context of current best clinical practice"],"prefix":"10.1186","volume":"22","author":[{"given":"Raphael","family":"Magnolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Laura","family":"Bottoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Capraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"10","key":"1294_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/j.1875-9114.2012.01123","volume":"32","author":"EJ Ip","year":"2012","unstructured":"Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910\u20139.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1294_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s11606-021-06751-3","volume":"36","author":"AK Bonnecaze","year":"2021","unstructured":"Bonnecaze AK, O\u2019Connor T, Burns CA. Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055\u201364.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1294_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1557988320966536","volume":"14","author":"AK Bonnecaze","year":"2020","unstructured":"Bonnecaze AK, O\u2019Connor T, Aloi JA. Characteristics and attitudes of men using anabolic androgenic steroids (AAS): a survey of 2385 men. Am J Mens Health. 2020;14(6): 1557988320966536.","journal-title":"Am J Mens Health"},{"key":"1294_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2017.02.039","volume":"464","author":"G Kanayama","year":"2018","unstructured":"Kanayama G, Pope HG. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4\u201313.","journal-title":"Mol Cell Endocrinol"},{"key":"1294_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14995","author":"C Mullen","year":"2020","unstructured":"Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: an update. Br J Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bph.14995.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1294_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11154-015-9320-5","volume":"16","author":"E Nieschlag","year":"2015","unstructured":"Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on non-reproductive organs and functions. Rev Endocr Metab Disord. 2015;16(3):199\u2013211.","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"1294_CR7","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s40279-017-0709-z","volume":"47","author":"MA Christou","year":"2017","unstructured":"Christou MA, Christou PA, Markozannes G, Tsatsoulis A, Mastorakos G, Tigas S. Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: a systematic review and meta-analysis. Sports Med. 2017;47(9):1869\u201383.","journal-title":"Sports Med"},{"key":"1294_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.124.071117","volume":"151","author":"J Windfeld-Mathiasen","year":"2025","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Tr\u00e6rup Andersen J, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation. 2025;151:828\u201334.","journal-title":"Circulation"},{"issue":"1","key":"1294_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9010097","volume":"9","author":"GD Albano","year":"2021","unstructured":"Albano GD, Amico F, Cocimano G, Liberto A, Maglietta F, Esposito M, et al. Adverse effects of anabolic-androgenic steroids: a literature review. Healthcare. 2021;9(1): 97.","journal-title":"Healthcare"},{"issue":"1","key":"1294_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.23736\/S0031-0808.22.04677-8","volume":"65","author":"M Esposito","year":"2023","unstructured":"Esposito M, Salerno M, Calvano G, Agliozzo R, Ficarra V, Sessa F, et al. Impact of anabolic androgenic steroids on male sexual and reproductive function: a systematic review. Panminerva Med. 2023;65(1):43\u201350.","journal-title":"Panminerva Med"},{"key":"1294_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1214374","volume":"10","author":"K Fadah","year":"2023","unstructured":"Fadah K, Gopi G, Lingireddy A, Blumer V, Dewald T, Mentz RJ. Anabolic androgenic steroids and cardiomyopathy: an update. Front Cardiovasc Med. 2023;10: 1214374.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"1294_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","volume":"23","author":"HG Pope","year":"2014","unstructured":"Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict. 2014;23(4):371\u20137.","journal-title":"Am J Addict"},{"key":"1294_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000822","author":"JE Skauen","year":"2023","unstructured":"Skauen JE, Pallesen S, Bj\u00f8rnebekk A, Chegeni R, Syvertsen A, Petr\u00f3czi A, et al. Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis. Curr Opin Endocrinol Diabetes Obes. 2023. https:\/\/doi.org\/10.1097\/MED.0000000000000822.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"1294_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.fertnstert.2014.02.002","volume":"101","author":"CD Rahnema","year":"2014","unstructured":"Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271\u20139.","journal-title":"Fertil Steril"},{"key":"1294_CR15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0358","author":"P Solanki","year":"2023","unstructured":"Solanki P, Eu B, Smith J, Allan C, Lee K. Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review. Endocr Connect. 2023. https:\/\/doi.org\/10.1530\/EC-23-0358.","journal-title":"Endocr Connect"},{"issue":"2","key":"1294_CR16","doi-asserted-by":"publisher","DOI":"10.57187\/s.4225","volume":"155","author":"R Magnolini","year":"2025","unstructured":"Magnolini R, Kossinna K, Bjasch D, Kruijver M, Bruggmann P, Senn O. Feasibility of implementing current best clinical practice for people who are using anabolic androgenic steroids within a Swiss primary care practice: a quality assurance study. Swiss Med Wkly. 2025;155(2): 4225. https:\/\/doi.org\/10.57187\/s.4225.","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"1294_CR17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache. 2013;53(10):1541\u20137.","journal-title":"Headache"},{"issue":"1","key":"1294_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-023-00573-8","volume":"18","author":"B Grant","year":"2023","unstructured":"Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P, et al. The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men. Subst Abuse Treat Prev Policy. 2023;18(1): 66.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"6","key":"1294_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ejendo\/lvad164","volume":"189","author":"B Grant","year":"2023","unstructured":"Grant B, Campbell J, Pradeep A, Burns AD, Bassett P, Abbara A, et al. Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study. Eur J Endocrinol. 2023;189(6):601\u201310.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1294_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207535","volume":"13","author":"A Zeeck","year":"2018","unstructured":"Zeeck A, Welter V, Alatas H, Hildebrandt T, Lahmann C, Hartmann A. Muscle dysmorphic disorder inventory (MDDI): validation of a German version with a focus on gender. PLoS ONE. 2018;13(11): e0207535.","journal-title":"PLoS ONE"},{"issue":"6","key":"1294_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1176\/appi.ajp.2009.08111699","volume":"166","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642\u20135.","journal-title":"Am J Psychiatry"},{"issue":"38","key":"1294_CR22","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1294_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1477-7525-1-15","volume":"1","author":"LA Heinemann","year":"2003","unstructured":"Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, et al. The Aging Males\u2019 Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1294_CR24","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/andr.12770","volume":"8","author":"G Corona","year":"2020","unstructured":"Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology. Andrology. 2020;8(5):970\u201387.","journal-title":"Andrology"},{"issue":"2","key":"1294_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107\u201317.","journal-title":"N Engl J Med"},{"key":"1294_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1201696","volume":"14","author":"S De Vincentis","year":"2023","unstructured":"De Vincentis S, Rochira V. Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment. Front Endocrinol (Lausanne). 2023;14: 1201696.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"1294_CR27","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1161\/CIRCRESAHA.124.324805","volume":"134","author":"JM Afolabi","year":"2024","unstructured":"Afolabi JM, Kirabo A. HIV and cardiovascular disease. Circ Res. 2024;134(11):1512\u20134.","journal-title":"Circ Res"},{"issue":"1","key":"1294_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nefroe.2019.06.005","volume":"40","author":"SLA Parente Filho","year":"2020","unstructured":"Parente Filho SLA, Gomes PEAC, Forte GA, Lima LLL, Silva J\u00fanior GBD, Meneses GC, et al. Kidney disease associated with androgenic-anabolic steroids and vitamin supplements abuse: be aware! Nefrologia (Engl Ed). 2020;40(1):26\u201331.","journal-title":"Nefrologia (Engl Ed)"},{"issue":"5","key":"1294_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40279-022-01801-0","volume":"53","author":"JM Smoliga","year":"2023","unstructured":"Smoliga JM, Wilber ZT, Robinson BT. Premature death in bodybuilders: what do we know? Sports Med. 2023;53(5):933\u201348.","journal-title":"Sports Med"},{"issue":"1","key":"1294_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13734-4","volume":"22","author":"R Magnolini","year":"2022","unstructured":"Magnolini R, Falcato L, Cremonesi A, Schori D, Bruggmann P. Fake anabolic androgenic steroids on the black market - a systematic review and meta-analysis on qualitative and quantitative analytical results found within the literature. BMC Public Health. 2022;22(1): 1371.","journal-title":"BMC Public Health"},{"key":"1294_CR31","doi-asserted-by":"publisher","DOI":"10.57187\/smw.2023.40080","volume":"153","author":"M Kruijver","year":"2023","unstructured":"Kruijver M, Bruggmann P, Magnolini R. Evidence of use and users of image- and performance-enhancing drugs in sports in Switzerland: a scoping literature review and implications for Swiss drug policy. Swiss Med Wkly. 2023;153: 40080.","journal-title":"Swiss Med Wkly"},{"issue":"5","key":"1294_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","volume":"24","author":"D Sagoe","year":"2014","unstructured":"Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. 2014;24(5):383\u201398.","journal-title":"Ann Epidemiol"},{"key":"1294_CR33","first-page":"843","volume":"21","author":"S Iff","year":"2021","unstructured":"Iff S, Butzke I, Quednow B, Gupta R, Imboden C, Claussen M. \u00abImage and performance enhancing drugs\u00bb im Freizeitsport. Swiss Med Forum. 2021;21:843\u20137.","journal-title":"Swiss Med Forum"},{"issue":"12","key":"1294_CR34","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1111\/j.1360-0443.2009.02734.x","volume":"104","author":"G Kanayama","year":"2009","unstructured":"Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966\u201378.","journal-title":"Addiction"},{"issue":"1","key":"1294_CR35","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1080\/07853890.2021.1995623","volume":"53","author":"M Szalavitz","year":"2021","unstructured":"Szalavitz M, Rigg KK, Wakeman SE. Drug dependence is not addiction-and it matters. Ann Med. 2021;53(1):1989\u201392.","journal-title":"Ann Med"},{"issue":"8","key":"1294_CR36","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2215-0366(23)00230-4","volume":"10","author":"MA Horowitz","year":"2023","unstructured":"Horowitz MA, Taylor D. Addiction and physical dependence are not the same thing. Lancet Psychiatry. 2023;10(8):e23.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1294_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7288-x","volume":"19","author":"O Harvey","year":"2019","unstructured":"Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1): 1024.","journal-title":"BMC Public Health"},{"issue":"3","key":"1294_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.12850","volume":"285","author":"H Horwitz","year":"2019","unstructured":"Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333\u201340.","journal-title":"J Intern Med"},{"issue":"2","key":"1294_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11154-020-09616-y","volume":"22","author":"D McCullough","year":"2021","unstructured":"McCullough D, Webb R, Enright KJ, Lane KE, McVeigh J, Stewart CE, et al. How the love of muscle can break a heart: impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health. Rev Endocr Metab Disord. 2021;22(2):389\u2013405.","journal-title":"Rev Endocr Metab Disord"},{"key":"1294_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3180","author":"J Windfeld-Mathiasen","year":"2024","unstructured":"Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Horwitz H. Mortality among users of anabolic steroids. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.3180.","journal-title":"JAMA"},{"issue":"3","key":"1294_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/20961790.2019.1595350","volume":"4","author":"AI Hern\u00e1ndez-Guerra","year":"2019","unstructured":"Hern\u00e1ndez-Guerra AI, Tapia J, Men\u00e9ndez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci Res. 2019;4(3):267\u201373.","journal-title":"Forensic Sci Res"},{"key":"1294_CR42","doi-asserted-by":"publisher","first-page":"732318","DOI":"10.3389\/frph.2021.732318","volume":"3","author":"DL Smit","year":"2021","unstructured":"Smit DL, Voogel AJ, den Heijer M, de Ronde W. Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac. Dysfunction echocardiography results of the HAARLEM study. Front Reprod Health. 2021;3:732318.","journal-title":"Front Reprod Health"},{"issue":"5","key":"1294_CR43","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ehf2.12494","volume":"6","author":"S Doleeb","year":"2019","unstructured":"Doleeb S, Kratz A, Salter M, Thohan V. Strong muscles, weak heart: testosterone-induced cardiomyopathy. ESC Heart Fail. 2019;6(5):1000\u20134.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"1294_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-014-0482-4","volume":"16","author":"V Mohsenin","year":"2014","unstructured":"Mohsenin V. Obstructive sleep apnea and hypertension: a critical review. Curr Hypertens Rep. 2014;16(10): 482.","journal-title":"Curr Hypertens Rep"},{"key":"1294_CR45","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2025.9904","author":"B Basheer","year":"2025","unstructured":"Basheer B, Ila V, Barros R, Mesquita F, Lopes LS, Lima VFN, et al. Management of adverse effects in testosterone replacement therapy. Int Braz J Urol. 2025. https:\/\/doi.org\/10.1590\/s1677-5538.ibju.2025.9904.","journal-title":"Int Braz J Urol"},{"key":"1294_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/540398","volume":"2012","author":"G Lugo","year":"2012","unstructured":"Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012: 540398.","journal-title":"Int J Endocrinol"},{"issue":"21","key":"1294_CR47","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.116.026945","volume":"135","author":"AL Baggish","year":"2017","unstructured":"Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991\u20132002.","journal-title":"Circulation"},{"issue":"9","key":"1294_CR48","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/bjsports-2016-097331","volume":"51","author":"JA Drezner","year":"2017","unstructured":"Drezner JA, Sharma S, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International criteria for electrocardiographic interpretation in athletes: consensus statement. Br J Sports Med. 2017;51(9):704\u201331.","journal-title":"Br J Sports Med"},{"issue":"3","key":"1294_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/bjsports-2012-092067","volume":"47","author":"JA Drezner","year":"2013","unstructured":"Drezner JA, Ackerman MJ, Anderson J, Ashley E, Asplund CA, Baggish AL, et al. Electrocardiographic interpretation in athletes: the \u201cSeattle criteria.\u201d Br J Sports Med. 2013;47(3):122\u20134.","journal-title":"Br J Sports Med"},{"issue":"1","key":"1294_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2015.04.004","volume":"170","author":"EH Estes","year":"2015","unstructured":"Estes EH, Zhang ZM, Li Y, Tereschenko LG, Soliman EZ. The romhilt-estes left ventricular hypertrophy score and its components predict all-cause mortality in the general population. Am Heart J. 2015;170(1):104\u20139.","journal-title":"Am Heart J"},{"issue":"5","key":"1294_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.acvd.2015.03.003","volume":"108","author":"PY Courand","year":"2015","unstructured":"Courand PY, Lantelme P, Gosse P. Electrocardiographic detection of left ventricular hypertrophy: time to forget the Sokolow-Lyon index? Arch Cardiovasc Dis. 2015;108(5):277\u201380.","journal-title":"Arch Cardiovasc Dis"},{"key":"1294_CR52","volume-title":"StatPearls [Internet]","author":"AA Pillai","year":"2025","unstructured":"Pillai AA, Fazal S, Mukkamalla SKR, Babiker HM. Polycythemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025."},{"issue":"5","key":"1294_CR53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/s-2007-996121","volume":"23","author":"JJ Michiels","year":"1997","unstructured":"Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23(5):441\u201354.","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"1294_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1055\/s-0038-1670639","volume":"44","author":"S Chang","year":"2018","unstructured":"Chang S, M\u00fcnster AB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost. 2018;44(8):734\u201346.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"1294_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.sxmr.2017.04.001","volume":"6","author":"SJ Ohlander","year":"2018","unstructured":"Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77\u201385.","journal-title":"Sex Med Rev"},{"issue":"10","key":"1294_CR56","doi-asserted-by":"publisher","first-page":"e240283","DOI":"10.1530\/EC-24-0283","volume":"13","author":"P Bond","year":"2024","unstructured":"Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283.","journal-title":"Endocr Connect"},{"issue":"6","key":"1294_CR57","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1086\/313816","volume":"30","author":"H Furrer","year":"2000","unstructured":"Furrer H. Prevalence and clinical significance of splenomegaly in asymptomatic human immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. Clin Infect Dis. 2000;30(6):943\u20135.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1294_CR58","doi-asserted-by":"publisher","first-page":"e14062","DOI":"10.1111\/and.14062","volume":"53","author":"JO Vilar Neto","year":"2021","unstructured":"Vilar Neto JO, da Silva CA, Bruno da Silva CA, Pinto DV, Caminha JSR, de Matos RS, et al. Anabolic androgenic steroid-induced hypogonadism, a reversible condition in male individuals? A systematic review. Andrologia. 2021;53(7):e14062.","journal-title":"Andrologia"},{"issue":"3","key":"1294_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-2003-39089","volume":"24","author":"E van Breda","year":"2003","unstructured":"van Breda E, Keizer HA, Kuipers H, Wolffenbuttel BH. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int J Sports Med. 2003;24(3):195\u20136.","journal-title":"Int J Sports Med"},{"key":"1294_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2024.102810","volume":"13","author":"IA Havnes","year":"2024","unstructured":"Havnes IA, Henriksen HCB, Johansen PW, Bj\u00f8rnebekk A, Neupane SP, Hisdal J, et al. Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) - a pilot study protocol. MethodsX. 2024;13: 102810.","journal-title":"MethodsX"},{"issue":"4","key":"1294_CR61","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/humrep\/deaa366","volume":"36","author":"DL Smit","year":"2021","unstructured":"Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Hum Reprod. 2021;36(4):880\u201390.","journal-title":"Hum Reprod"},{"issue":"3","key":"1294_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","volume":"390","author":"PJ Snyder","year":"2024","unstructured":"Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203\u201311.","journal-title":"N Engl J Med"},{"issue":"8","key":"1294_CR63","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1210\/clinem\/dgae334","volume":"109","author":"S Bhasin","year":"2024","unstructured":"Bhasin S, Thompson IM. Prostate risk and monitoring during testosterone replacement therapy. J Clin Endocrinol Metab. 2024;109(8):1975\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"1294_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.peh.2024.100283","author":"HCB Henriksen","year":"2024","unstructured":"Henriksen HCB, J\u00f8rgensen AP, Bj\u00f8rnebekk A, Neupane SP, Havnes IA. Clomiphene citrate and optional human chorionic gonadotropin for treating male hypogonadism arising from long-term anabolic-androgenic steroid use\u2014a pilot study. Performance Enhancement Health. 2024. https:\/\/doi.org\/10.1016\/j.peh.2024.100283.","journal-title":"Performance Enhancement Health"},{"key":"1294_CR65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/26338076231209044","volume":"57","author":"T Piatkowski","year":"2024","unstructured":"Piatkowski T, Gibbs N, Dunn M. Beyond the law: on Etiocaasu, help-seeking and health outcomes in Australia. J Criminol. 2024;57:62\u201382. https:\/\/doi.org\/10.1177\/26338076231209044.","journal-title":"J Criminol"},{"issue":"2","key":"1294_CR66","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.peh.2023.100247","volume":"11","author":"M Dunn","year":"2023","unstructured":"Dunn M, Piatkowski T, Whiteside B, Eu B. Exploring the experiences of general practitioners working with patients who use performance and image enhancing drugs. Perform Enhanc Health. 2023;11(2):100247. https:\/\/doi.org\/10.1016\/j.peh.2023.100247.","journal-title":"Perform Enhanc Health"},{"issue":"5","key":"1294_CR67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob Adv Health Med. 2013;2(5):38\u201343.","journal-title":"Glob Adv Health Med"},{"key":"1294_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2020.108660","volume":"161","author":"FAC Seara","year":"2020","unstructured":"Seara FAC, Olivares EL, Nascimento JHM. Anabolic steroid excess and myocardial infarction: from ischemia to reperfusion injury. Steroids. 2020;161: 108660.","journal-title":"Steroids"},{"issue":"18","key":"1294_CR69","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1097\/CM9.0000000000000407","volume":"132","author":"JD Liu","year":"2019","unstructured":"Liu JD, Wu YQ. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl). 2019;132(18):2229\u201336.","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"1294_CR70","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MED.0000000000000759","volume":"29","author":"DL Smit","year":"2022","unstructured":"Smit DL, Bond P, de Ronde W. Health effects of androgen abuse: a review of the HAARLEM study. Curr Opin Endocrinol Diabetes Obes. 2022;29(6):560\u20135.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1294_CR71","doi-asserted-by":"publisher","first-page":"1059473","DOI":"10.3389\/fendo.2022.1059473","volume":"13","author":"P Bond","year":"2022","unstructured":"Bond P, Smit DL, de Ronde W. Anabolic-androgenic steroids: How do they work and what are the risks? Front Endocrinol (Lausanne). 2022;13:1059473.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1294_CR72","first-page":"1331","volume":"38","author":"LR Gagnon","year":"2022","unstructured":"Gagnon LR, Sadasivan C, Perera K, Oudit GY. Cardiac complications of common drugs of abuse: pharmacology, toxicology, and management. Can J Cardiol. 2022;38(9):1331\u201341.","journal-title":"Can J Cardiol"},{"issue":"3","key":"1294_CR73","first-page":"363","volume":"35","author":"OJ Ilonze","year":"2022","unstructured":"Ilonze OJ, Enyi CO, Ilonze CC. Cardiomyopathy and heart failure secondary to anabolic-androgen steroid abuse. Proc (Bayl Univ Med Cent). 2022;35(3):363\u20135.","journal-title":"Proc (Bayl Univ Med Cent)"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01294-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01294-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:03:54Z","timestamp":1757441034000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01294-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01294-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report does not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has read the final manuscript for initial submission and provided informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. We can report that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}